Clinical trial · Observational
Resistance to Immunotherapy in Gastric Cancer
Mechanisms of Resistance to Immunotherapy Based on Checkpoint Inhibitors in Metastatic Gastric Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project seeks to analyze and define the mechanism (s) involved in the resistance to checkpoint therapy in metastatic GC patients. The investigators propose the use of a Next-Generation Sequencing (NGS) assay that involves 395 genes allowing us to define a specific molecular signature to characterize responder and non-responder patients to checkpoint therapy in combination with IHC analyses of specific factors. Such signature (s) could then be used to predict which individuals who might get the most benefit out of checkpoint therapy treatment. Analysis will be perfomed retrospectively using biopsies provided by mGC patients recruited at the Red de Salud UC treated with checkpoint therapy, the response of patients to treatment is evaluated by RECIST 1.1 criteria and thereby they are classified as "responders" or "non-responders".
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy responders/non-responders | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Immunotherapy responders/non-responders
- description
- paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
- interventionNames
- Other: Immunotherapy responders/non-responders
Primary outcomes (1)
- measure
- Survival
- timeFrame
- 3-12 weeks
- description
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Chilean residents, male or female \>18 yr-old * Histologically confirmed metastatic gastric cancer * Received immunotherapy using checkpoint inhibitors with clinical followup for at least 6 weeks * Patients with paraffin samples or biopsies obtained form primary tumor * Able to speak and understand Spanish and sign a written informed consent form Exclusion Criteria: * Patients without clinical records or no paraffin or biopsy sample
References
Publications (0)
Data not yet available